Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond

Bibliography

• Bennett JM, Catovsky D, Daniel MT, Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99
   PubMed Web of Science ®Google Scholar
• Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82:358-67
   PubMed Web of Science ®Google Scholar
• Germing U, Gattermann N, Strupp C, Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983-92
   PubMed Web of Science ®Google Scholar
• Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109:1536-42
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000;13:193-207
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88
   PubMed Web of Science ®Google Scholar
• Crawford J, Cella D, Cleeland CS, Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-95
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Cella D, Nortier JW, Epoetin Alfa Study Group. Erythropoietin improves quality of life. Lancet Oncol 2002;3:459-60
   PubMed Web of Science ®Google Scholar
• Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006;4:91-6
   PubMedGoogle Scholar
• Kelaidi C, Stamatoullas A, Beyne-Rauzy O, Myelodysplastic syndrome (MDS) in France: results of a one-week cross-sectional survey on daily practice management in 919 patients by the GFM. ASH Annual Meeting Abstracts. Blood 2008;112:2672
   Google Scholar
• Italian Coopoerative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998;103:1070-4
   PubMed Web of Science ®Google Scholar
• Thompson JA, Gilliland DG, Prchal JT, Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 2000;95:1175-9
   PubMed Web of Science ®Google Scholar
• Casadevall N, Durieux P, Dubois S, Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104:321-7
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25
   PubMed Web of Science ®Google Scholar
• Park S, Grabar S, Kelaidi C, Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574-82
   PubMed Web of Science ®Google Scholar
• Jädersten M, Malcovati L, Dybedal I, Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:3607-13
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Sun Z, Miller KB, Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized Phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009;114(12):2393-400
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Negrin R, Stein R, Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997;99:344-51
   PubMed Web of Science ®Google Scholar
• Wilson J, Yao GL, Raftery J, A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-202, iii-iv
   PubMed Web of Science ®Google Scholar
• Lanthier M, Behrman R, Nardinelli C. Economic issues with follow-on protein products. Nat Rev Drug Discov 2008;7:733-7
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Rossert J, Casadevall N, A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009;361:1848-55
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
   PubMed Web of Science ®Google Scholar
• Elliott S, Lorenzini T, Asher S, Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-21
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Gray SJ, Elston O, Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5
   PubMed Web of Science ®Google Scholar
• Agoram B, Aoki K, Sameer Doshi, Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci 2009;98:2198-211
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 2007;22(Suppl 4):iv2-iv9
   PubMedGoogle Scholar
• Heatherington AC, Dittrich C, Sullivan JT, Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. Clin Pharmacokinet 2006;45:199-211
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Arena F, Patel D, A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 2004;100:859-68
   PubMed Web of Science ®Google Scholar
• Hedenus M, Hansen S, Taylor K, Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86
   PubMed Web of Science ®Google Scholar
• Musto P, Lanza F, Balleari E, Darbepoetin alpha for the treatment of anaemia in low–intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204-9
   PubMed Web of Science ®Google Scholar
• Stasi R, Abruzzese E, Lanzetta G, Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005;16:1921-7
   PubMed Web of Science ®Google Scholar
• Mannone L, Gardin C, Quarre MC, High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006;133:513-9
   PubMed Web of Science ®Google Scholar
• Giraldo P, Nomdedeu B, Loscertales J, ; Aranesp in Myelodysplastic Syndromes (ARM) Study Group. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006;107:2807-16
   PubMed Web of Science ®Google Scholar
• Gabrilove J, Paquette R, Lyons RM, Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008;142:379-93
   PubMed Web of Science ®Google Scholar
• Gotlib J, Lavori P, Quesada S, A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 2009;84:15-20
   PubMed Web of Science ®Google Scholar
• Seidenfeld J, Piper M, Flamm C, Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-14
   PubMed Web of Science ®Google Scholar
• Ross SD, Allen IE, Probst CA, Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007;12:1264-73
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49
   PubMed Web of Science ®Google Scholar
• Scrijvers D, Roila F, ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use. Ann Oncol 2009;20:159-61
   PubMed Web of Science ®Google Scholar
• Myelodysplastic syndromes. NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA; National Comprehensive Cancer Network 2009. Available from: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf [Last accessed 18 February 2010]
   Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24
   PubMed Web of Science ®Google Scholar
• Casadevall N, Dupuy E, Molho-Sabatier P, Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334:630-3
   PubMed Web of Science ®Google Scholar
• Bennett CL, Luminari S, Nissenson AR, Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-8
   PubMed Web of Science ®Google Scholar
• Roger SD, Suranyi MG, Walker RG, A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease. Curr Med Res Opin 2008;24:2181-7
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
   PubMed Web of Science ®Google Scholar
• Ludwig H, Crawford J, Osterborg A, Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838-47
   PubMed Web of Science ®Google Scholar
• Bastit L, Vandebroek A, Altintas S, Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-8
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Farris A, Del Prete S, Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-25
   PubMed Web of Science ®Google Scholar
• Musto P, Modoni S, Alicino G, Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 1994;79:493-9
   PubMed Web of Science ®Google Scholar